V Wealth Advisors’s Seres Therapeutics MCRB Stock Holding History

V Wealth Advisors’s Portfolio MCRB Stock Details MCRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-55	Closed	-$12K	–	505
2017 Q2	$12K	Buy	+55	New	+$11.3K	0.01%	535

Other funds holding MCRB

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

V Wealth Advisors's MCRB Position: Q3 2017 in Review

V Wealth Advisors sold out of Seres Therapeutics (MCRB) in Q3 2017, closing a stake of 55 shares — an estimated $12K sold.

V Wealth Advisors first reported a position in MCRB in Q2 2017 and held it in 1 quarter. The position peaked at $12K in Q2 2017. 80 funds tracked by Wall St. Rank hold MCRB as of Q3 2017.

V Wealth Advisors reported no remaining Seres Therapeutics position as of Q3 2017 after selling out during the quarter.
V Wealth Advisors sold 55 Seres Therapeutics shares in Q3 2017, an estimated $12K.
V Wealth Advisors first reported a position in Seres Therapeutics in Q2 2017 and held it in 1 quarter.
V Wealth Advisors's Seres Therapeutics position peaked at $12K in Q2 2017.
80 funds tracked by Wall St. Rank held Seres Therapeutics as of Q3 2017.

Based on V Wealth Advisors's 13F filing for Q3 2017, filed 12 Oct 2017.